Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards (OnkoBot)

November 9, 2026 updated by: Lisa Adams, Technical University of Munich

OnkoBot: Prospective Shadow-Mode Evaluation of a Locally Operated, Source-Grounded Large Language Model System for Drafting Multidisciplinary Tumor Board Recommendations

This study tests whether an artificial intelligence (AI) system that drafts tumor board recommendations performs as well on new cases as it did on archived cases. The system runs in shadow mode at three multidisciplinary tumor boards of TUM University Hospital rechts der Isar. For each case it drafts a recommendation before the board meets. The board does not see the draft, and the draft has no influence on patient care. After the meeting, each draft is compared with the board decision. The agreement rate is then compared with the rate measured on archived decisions of the same boards.

Study Overview

Detailed Description

The system is a locally operated large language model (LLM) pipeline with retrieval-augmented generation. Its input is the case as presented to the board, with diagnosis, course, question and all patient documents dated before the board date. It retrieves guideline recommendations (Onkopedia and AWMF S3 guidelines in the version in force on the board date), laboratory values, precedent cases from the board archive and PubMed abstracts published before the board date. It then drafts a recommendation with justification. Each statement of the draft is linked to a verbatim quote from its source. All models run on local GPU servers of the hospital with no data retention beyond the immediate analysis, and no patient data are sent to external providers.

The study includes the hematology board, the orthopedics and sarcoma board and the head and neck board. For each case registered for a session, the system drafts a recommendation after the pre-board documents are pulled and before the session starts. Board members do not see the drafts. The decision pipeline (generator Gemma-4-31B at temperature 0) is frozen and versioned for the study period. The study uses routine clinical data only. Patients are not contacted, and no study-specific procedures are performed.

The draft is compared with the consensus decision in the board report. An LLM judge (GLM-5.3-Flash, majority of three votes) assigns both texts to one of seven decision categories: systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care and referral to the molecular tumor board. It also scores agreement in substance from 0 to 3 and records the direction of any disagreement. The judge was validated against clinician ratings on a sealed test set. The same prompt version is used to score the prospective cases and the retrospective reference sample, separately from any output that clinicians see.

The retrospective reference is the evaluation sample of archived decisions of the same three boards (about 2,000 cases, one per patient, drawn with a fixed seed and stratified by time). Patients who also appear in the prospective cohort are removed from the reference. The primary analysis tests non-inferiority of the prospective category match rate against the retrospective rate, pooled over the three boards, with a margin of 7.5 percentage points and a one-sided alpha of 0.025. The variance is cluster-robust for board sessions. A case without a draft counts as not concordant. Per-board results are reported descriptively with 95% confidence intervals. An exploratory component evaluates a trial-matching engine that proposes recruiting clinical trials per case.

In a subset of 30 to 50 cases per board, physicians rate the system draft against the board decision. This subset tests whether the agreement between judge and clinicians, measured retrospectively, also holds prospectively.

Study Type

Observational

Enrollment (Estimated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Bavaria
      • Munich, Bavaria, Germany, 81675
        • Not yet recruiting
        • TUM University Hospital rechts der Isar
      • Munich, Bavaria, Germany
        • Recruiting
        • TUM Klinikum rechts der Isar
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All cases registered for the hematology, orthopedics and sarcoma, and head and neck tumor boards of TUM University Hospital rechts der Isar during the study period. One case is one patient presentation on one board date.

Description

Inclusion Criteria:

  • Case registered for a session of a participating tumor board (hematology, orthopedics and sarcoma, head and neck) of TUM University Hospital rechts der Isar during the study period
  • Board registration and pre-board patient documents available before the session starts

Exclusion Criteria:

  • Case not discussed at the session, defined as no board report with a consensus decision for that date (deferred or withdrawn registrations)
  • Session without a shadow run of the system

Excluded cases are counted and reported by reason.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hematology board

Consecutive cases presented at the hematology tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Orthopedics and sarcoma board

Consecutive cases presented at the orthopedics and sarcoma tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Head and neck board

Consecutive cases presented at the head and neck tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Cases With Category Match Between System Draft and Board Decision
Time Frame: Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)

Proportion of discussed cases in which the system draft and the board consensus decision fall into the same of seven decision categories (systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care, referral to the molecular tumor board). Overlap counts where either side carries a second category. Assessed by a pre-specified LLM judge (GLM-5.3-Flash, prompt V3, majority of three votes), pooled over the three boards. Tested for non-inferiority against the rate of the same system and judge on the retrospective reference sample of the same boards, margin 7.5 percentage points, one-sided alpha 0.025.

Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Cases Rated Concordant or Partially Concordant
Time Frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Category match with a substance score of at least 1 of 3 (concordant requires at least 2 of 3 on a primary-category match, 3 of 3 where only second categories overlap). Non-inferiority versus retrospective reference, margin 7.5 percentage points, tested after the primary outcome (hierarchical testing).

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases Rated Concordant, Partially Concordant and Not Concordant
Time Frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Proportion of cases rated concordant, partially concordant and not concordant by the LLM judge.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match per Board
Time Frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Category match and concordant or partially concordant per board, with 95% confidence intervals, descriptive.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Discordant Cases by Direction of Disagreement
Time Frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Among cases without category match, proportion in which the draft is more conservative, more aggressive or a different modality than the board decision.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match as Rated by Clinicians
Time Frame: Within 3 months after the board session

In 30 to 50 cases per board, agreement between draft and board decision as rated by physicians who did not attend the session, and agreement between judge and clinicians on category match (percentage agreement, Cohen's kappa).

Within 3 months after the board session
Proportion of Citations Verified Word for Word Against Their Source
Time Frame: At draft generation, before the board session

Proportion of citations per case that verify word for word against their source, and proportion of cases in which every citation verifies.

At draft generation, before the board session
Proportion of Cases With a Draft Completed Before the Board Session
Time Frame: At draft generation, before the board session

Proportion of cases with a draft completed before the session starts, and generation time per case in minutes.

At draft generation, before the board session

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Clinical Trials Shortlisted per Case by the Trial-Matching Engine
Time Frame: At draft generation, before the board session

Number of trials shortlisted per case, proportion recruiting on the board date, rule-based error rate (wrong disease, line of therapy, setting or status) and clinician screening verdicts where given.

At draft generation, before the board session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lisa Adams, MD, Technical University of Munich
  • Principal Investigator: Krischan Braitsch, MD, Technical University of Munich

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 9, 2026

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

April 30, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data are routine clinical records that may not leave the hospital under the ethics approval and data protection concept. Aggregate results and the analysis code will be published.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe